Featured Research

from universities, journals, and other organizations

Clot-Buster Keeps Heart Devices Humming

Date:
September 17, 2002
Source:
American Heart Association
Summary:
Injecting a clot-buster unclogged a mechanical heart pump, restoring blood flow, according to a study in Circulation: Journal of the American Heart Association.

DALLAS, Sept. 17 – Injecting a clot-buster unclogged a mechanical heart pump, restoring blood flow, according to a study in today's special surgery issue of Circulation: Journal of the American Heart Association.

"This is such a simple solution to a very serious problem for heart failure patients who receive left ventricular assist devices (LVADs)," says lead author Markus Rothenburger, M.D., a resident in cardiovascular surgery at University Hospital in Muenster, Germany.

An LVAD is a mechanical pump-type device surgically implanted to maintain the pumping ability of a heart that can't effectively work on its own. Clot-busting drugs, also known as thrombolytic therapy, dissolve blood clots that impair blood flow. Most LVADs are based on a pulsatile blood flow. It has been reported that up to 47 percent of all patients with a pulsatile LVAD develop clotting complications, according to the report.

The recently introduced MicroMed DeBakey VAD, the device used in this study, differs from other LVADs in that it generates a continuous blood flow rather than a pulsing one. Their advantage over similar devices is smaller size, which seems to have reduced the incidence of thromboembolism and infections. It is also quieter.

Thromboembolism is a blood clot that moves through the blood stream before blocking an artery. "Despite these advances, its axial pump seems to be associated with a higher risk for clot formation, which then might cause device malfunction and peripheral thromboembolism," Rothenburger says.

"Our study shows that this serious complication can be treated effectively with intravenous administration of rt-PA. Exchange of the device, in most cases, is not necessary," he says.

The researchers followed 22 patients, 20 men and two women, with the MicroMed DeBakey VAD, finding that the pump flow was critically reduced in eight patients. In seven cases, the pump worked harder, which indicates clot formation inside the device. In one case, the demand on the pump was very low, indicating that a clot was in the opening of the device.

No emergency surgical device exchange was necessary after receiving rt-PA. No severe bleeding complications occurred, which can be a side effect of thrombolytic therapy. Four patients did have nose bleeds for three days. All patients were discharged from intensive care immediately after discontinuing rt-PA. Six patients went on to successful heart transplantation and two died on LVAD support because of multiorgan failure.

"Thrombolytic therapy with rt-PA is an effective and easily applicable treatment for clot formation inside the MicroMed DeBakey VAD," says Rothenburger.

Other co-authors are D. Hammel, M.D.; C. Schmidt, M.D.; T.D.T. Tjan, M.D.; D. Bocker, M.D.; H.H. Scheld, M.D.; and C. Schmid, M.D.


Story Source:

The above story is based on materials provided by American Heart Association. Note: Materials may be edited for content and length.


Cite This Page:

American Heart Association. "Clot-Buster Keeps Heart Devices Humming." ScienceDaily. ScienceDaily, 17 September 2002. <www.sciencedaily.com/releases/2002/09/020917071959.htm>.
American Heart Association. (2002, September 17). Clot-Buster Keeps Heart Devices Humming. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2002/09/020917071959.htm
American Heart Association. "Clot-Buster Keeps Heart Devices Humming." ScienceDaily. www.sciencedaily.com/releases/2002/09/020917071959.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins